Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Clinical Studies The safety and effectiveness of EGRIFTA WR (11.6 mg/vial formulation) has been established based on adequate and well controlled studies with EGRIFTA (1 mg/vial formulation), as well as a demonstration of comparable bioavailability between the 1.28 mg EGRIFTA WR dose (11.6 mg/vial formulation) and the 2 mg EGRIFTA dose (1 mg/vial formulation) [see CLINICAL PHARMACOLOGY ]
Inject 1 cm above or below this line, alternating between injections
Response: We appreciate the concerns the commenter has raised
A concentration where the target dose falls on a round syringe mark eliminates the mental arithmetic that produces dosing errors
Patients at ASCs also may undergo multiple elective procedures, so they could receive duplicative patient surveys
If a day is missed, the research-sensible response is simply to resume the next scheduled dose, not to double up, because there is no acute deficit to make good and doubling only departs from the documented figure
US$ 21.77
US$ 20.55
US$ 26.22
US$ 26.17
